AOD-9604 Peptide

## What it is AOD-9604 is a synthetic modified peptide corresponding to residues 176 to 191 of the human growth hormone C-terminus, with an additional tyrosine residue added to improve pharmacokinetic stability. It was developed by Metabolic Pharmaceuticals (Australia) in the late 1990s under the leadership of Frank Ng, with the explicit goal of retaining GH's lipolytic activity in adipose tissue while excluding its growth-promoting effects mediated through the GH receptor and IGF-1 axis. The molecular thesis was that the lipolytic effects of GH could be dissociated from its insulin-antagonizing and growth-stimulating activity, producing a cleaner anti-obesity drug. The phase 2 development program ran through the early 2000s and concluded with disappointing results: obese patients showed no statistically meaningful weight or fat-mass loss versus placebo over 12 weeks at doses up to 1 mg daily. Metabolic discontinued the obesity drug program in 2007. The compound has since persisted in the research-peptide and compounded supplement markets, marketed for fat loss largely on the basis of preclinical mechanism and despite the negative phase 2 readout. Users tend to be body-composition-focused individuals seeking adjunctive fat loss alongside diet and training, and a smaller cohort exploring it for joint comfort or cartilage-related claims that rest on weak preclinical signals. AOD-9604 is not approved as a drug in any major jurisdiction. It received GRAS (generally recognized as safe) status in some compounding contexts in the US, which has been used to market it as a supplement, but this is not the same as FDA drug approval. ## Mechanism of action AOD-9604 is proposed to stimulate beta-3 adrenergic receptor signaling in adipocytes, increasing lipolysis and fatty-acid oxidation. The fragment was specifically designed to lack engagement with the GH receptor and the JAK2/STAT5 signaling cascade that mediates IGF-1 induction, so in theory it produces lipolysis without raising IGF-1 or impairing insulin sensitivity. Preclinical work in rodent and ex vivo adipocyte models supports the lipolytic activity claim. The pharmacokinetics in humans are short. Plasma half-life is approximately 30 minutes, and peak plasma concentration occurs around 1 to 2 hours post subcutaneous injection. The brevity of plasma exposure is one of several reasons the phase 2 obesity program may have failed to translate the preclinical signal into clinical weight loss. ## Evidence base The pivotal Heffernan 2001 phase 2 trial (n=530 obese adults, 12 weeks) is the only published clinical evidence at scale. Participants received subcutaneous AOD-9604 at 0.25, 0.5, or 1 mg daily versus placebo. The primary endpoint was change in body weight; secondary endpoints included fat mass and lipid profile. None of the active dose arms showed statistically significant weight or fat-mass differences from placebo. Tolerability was good and adverse events were minimal, but the negative efficacy readout halted further obesity development. An earlier phase 1 study established acute safety and pharmacokinetics in healthy volunteers, with no notable adverse signals. A subsequent small Heffernan 2001b trial in obese men over 12 weeks reproduced the negative efficacy pattern. Preclinical evidence is more abundant and more positive. Ng 2000 and follow-up work documented increased lipolysis in rodent adipocytes and accelerated fat-mass loss in obese mouse models versus saline. Cartilage repair preclinical work in osteoarthritis models reported small improvements in cartilage histology, but these signals have not been validated in human OA outcome trials. The gap between preclinical lipolytic activity and clinical weight loss is the central reality of this molecule. Anecdotal user reports of fat loss are almost universally confounded by simultaneous calorie restriction and exercise, and any effect attributable to the peptide alone is indistinguishable from placebo or noise. The honest framing is that AOD-9604 is a preclinically interesting molecule that failed its definitive human trial. ## Dosage and administration Anecdotal protocols use 250 to 500 mcg subcutaneously once daily, typically before fasted morning training to align with putative lipolytic windows. Some protocols extend to 1 mg daily or split into morning and pre-bed administrations. The phase 2 trial tested up to 1 mg daily without efficacy benefit, so dose escalation beyond this is not supported by data. A typical 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL (2500 mcg/mL). A 300 mcg dose equals 12 units on a U100 insulin syringe; a 500 mcg dose equals 20 units. Injection rotates between abdomen, thigh, and deltoid. Reference the existing typicalDoseMg of 0.3 (300 mcg) and daily frequency. Anecdotal cycling protocols run 8 to 12 weeks on, then 4 weeks off. There is no controlled human cycling data because there is essentially no continuous-use clinical evidence beyond the 12-week phase 2 window. ## Side effects and safety Reported adverse effects are minimal. Heffernan 2001 documented a mild adverse-event profile indistinguishable from placebo in tolerability, with rare injection-site reactions and occasional transient mild headache. The absence of GH-receptor engagement explains the favorable side effect profile relative to direct GH or IGF-1 administration: AOD-9604 does not produce edema, carpal tunnel syndrome, insulin resistance, or growth-tissue effects characteristic of GH replacement. Contraindications include pregnancy, lactation, and unknown long-term safety profile for chronic use. Drug interactions are sparsely documented; theoretical antagonism with beta-blockers (which would block beta-3 adrenergic signaling) is plausible but not clinically validated. The compound is not explicitly listed on the WADA Prohibited List, but the broader S2 category covers GH-derived peptides and growth-factor analogs, so athletes should consult their national anti-doping body and avoid use during competition windows. ## Practical notes Lyophilized vials should be stored refrigerated. Reconstituted solution is typically stable for 2 to 4 weeks refrigerated. Light protection is sensible but not strictly required. Expect no detectable acute effect from individual doses. If any benefit accumulates, it is over weeks of consistent dosing combined with caloric deficit and structured training. Set realistic expectations grounded in the phase 2 readout: the molecule did not produce meaningful weight loss in 530 obese adults over 12 weeks, and there is no convincing human evidence that it produces meaningful weight loss now. Stack with semaglutide or tirzepatide protocols at your discretion, but the GLP-1 or dual-incretin agent is doing the meaningful work in any such combination. AOD-9604 is most honestly described as a research peptide with a negative pivotal trial that persists in the supplement market on the strength of mechanistic appeal rather than clinical effect.